[CAS NO. 1341200-45-0] Dubermatinib(TP-0903)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1341200-45-0]
Catalog
SLK-S7846
Brand
Selleck
CAS
1341200-45-0
DESCRIPTION [1341200-45-0]
Overview
| MDL | MFCD28502172 |
|---|---|
| Molecular Weight | 516.06 |
| Molecular Formula | C24H30ClN7O2S |
| SMILES | O=S(C1=CC=CC=C1NC2=NC(NC3=CC=C(CN4CCN(C)CC4)C=C3)=NC=C2Cl)(N(C)C)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9378 mL | 9.6888 mL | 19.3776 mL |
| 5 mM | 0.3876 mL | 1.9378 mL | 3.8755 mL |
| 10 mM | - | - | - |
| 50 mM | - | - | - |
Description
TP-0903 is a potent and selective Inhibitor with of 27 nM. TP-0903 is highly effective in inducing .
Targets
| Axl [1] (Cell-free assay) |
| 27 nM |
In vitro
In pancreatic cancer cells (PSN-1), TP-0903 shows strong antiproliferative activity with IC50 of 6 M. TP-0903 also induces strong G2/M arrest by potently inhibiting Aurora A and B. [1] In CLL B cells from all the patients with CLL, TP-0903 causes a dose-dependent induction of massive apoptosis by targeting phosphorylated Axl, and overcomes CLL BMSC-mediated protection of CLL B cells from apoptosis.
In vivo
In the adult rat hippocampus, the intracerebroventricular administration of SAG (2.5 nM) significantly increases the number of newly generated cells and extends survival of hippocampal cells. In mice, SAG (20 μg/g, i.p.) effectively prevents GC-induced neonatal cerebellar developmental abnormalities.
References
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.